A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Latest Information Update: 10 Jun 2024
At a glance
- Drugs THE 630 (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Theseus Pharmaceuticals
- 27 Jul 2023 Planned End Date changed from 1 Jun 2026 to 1 Feb 2024.
- 27 Jul 2023 Planned primary completion date changed from 1 Jun 2025 to 1 Feb 2024.
- 27 Jul 2023 Status changed to active, no longer recruiting.